Lynk Pharmaceutical (Hangzhou) Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lynk Pharmaceutical (Hangzhou) Co., Ltd.
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.